MedTrace Logo

Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)

NCT04602091 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2300

Last updated 2025-01-23

No results posted yet for this study

Summary

Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new class needs to be better defined and its use in real life further established.

The French Society of Rheumatologists intends to coordinate a prospective national registry study for this follow-up.

This registry will include at least 1500 Rheumatoid Arthritis (RA) and 150 patients with psoriatic arthritis from the start of treatment with JAK inhibitor and then followed for 5 years.

This registry is a longitudinal, multicentre, observational registry study. The objective of this national registry is to get a better understanding of the safety profiles of JAK inhibitors and get knowledge of their use in daily practice in order to optimize this use and potentially integrate JAK inhibitors into personalised medicine strategies.

This registry will generate efficacy data, especially therapeutic maintenance, observation, allowing inter-registry comparisons with other biologic compounds in the French population, and can be aggregated with other similar registries in other countries.

Conditions

Interventions

OTHER

no intervention

no intervention

Sponsors & Collaborators

  • Bordeaux PharmacoEpi

    collaborator OTHER

  • Societe Francaise de Rhumatologie

    lead OTHER

Principal Investigators

  • Marie-Elise TRUCHETET · CHU de Bordeaux - Pellegrin

  • Jerôme AVOUAC · AP-HP Hôpital Cochin

  • Clément PRATI · CHRU de Besançon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2027-12-31
Completion
2030-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04602091 on ClinicalTrials.gov